- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Piche Resources
Black Swan Graphene
Anax Metals Limited
Golden Mile Resources
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BiomX Announces Dual Listing on the Tel-Aviv Stock Exchange
BiomX announced that the Tel Aviv Stock Exchange has approved the listing of its common shares, with trading effective February 6th, 2020.
BiomX (NYSE:PHGE) announced that the Tel Aviv Stock Exchange (TASE) has approved the listing of its common shares, with trading effective February 6th, 2020.
As quoted in the press release:
The Company’s common shares will continue to trade on the NYSE American Stock Market, and the Company will continue to comply with the reporting and disclosure requirements of the U.S. Securities and Exchanges Commission, without any additional regulatory requirements.
“We are excited to begin trading on the Tel Aviv Stock Exchange in Israel, the country in which we were founded and are headquartered,” said BiomX CEO Jonathan Solomon. “We are proud to provide another route for Israeli investors to participate in our growth as a leading developer of targeted phage products. We particularly look forward to disclosing Phase 1 data for our lead acne program by the end of the first quarter of 2020 and Phase 1 data for our inflammatory bowel disease program in the second half of 2020.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.